RCEL Relative Valuation
RCEL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RCEL is overvalued; if below, it's undervalued.
Historical Valuation
AVITA Medical Inc (RCEL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.32. The fair price of AVITA Medical Inc (RCEL) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：3.55
Fair
-3.04
PE
1Y
3Y
5Y
Trailing
Forward
-5.29
EV/EBITDA
AVITA Medical Inc. (RCEL) has a current EV/EBITDA of -5.29. The 5-year average EV/EBITDA is 15.18. The thresholds are as follows: Strongly Undervalued below -167.90, Undervalued between -167.90 and -76.36, Fairly Valued between 106.71 and -76.36, Overvalued between 106.71 and 198.25, and Strongly Overvalued above 198.25. The current Forward EV/EBITDA of -5.29 falls within the Historic Trend Line -Fairly Valued range.
-3.85
EV/EBIT
AVITA Medical Inc. (RCEL) has a current EV/EBIT of -3.85. The 5-year average EV/EBIT is -7.00. The thresholds are as follows: Strongly Undervalued below -16.31, Undervalued between -16.31 and -11.65, Fairly Valued between -2.34 and -11.65, Overvalued between -2.34 and 2.31, and Strongly Overvalued above 2.31. The current Forward EV/EBIT of -3.85 falls within the Historic Trend Line -Fairly Valued range.
1.30
PS
AVITA Medical Inc. (RCEL) has a current PS of 1.30. The 5-year average PS is 6.45. The thresholds are as follows: Strongly Undervalued below -3.97, Undervalued between -3.97 and 1.24, Fairly Valued between 11.66 and 1.24, Overvalued between 11.66 and 16.87, and Strongly Overvalued above 16.87. The current Forward PS of 1.30 falls within the Historic Trend Line -Fairly Valued range.
-4.90
P/OCF
AVITA Medical Inc. (RCEL) has a current P/OCF of -4.90. The 5-year average P/OCF is -3.74. The thresholds are as follows: Strongly Undervalued below -82.95, Undervalued between -82.95 and -43.35, Fairly Valued between 35.86 and -43.35, Overvalued between 35.86 and 75.46, and Strongly Overvalued above 75.46. The current Forward P/OCF of -4.90 falls within the Historic Trend Line -Fairly Valued range.
-3.30
P/FCF
AVITA Medical Inc. (RCEL) has a current P/FCF of -3.30. The 5-year average P/FCF is -2.55. The thresholds are as follows: Strongly Undervalued below -85.27, Undervalued between -85.27 and -43.91, Fairly Valued between 38.81 and -43.91, Overvalued between 38.81 and 80.17, and Strongly Overvalued above 80.17. The current Forward P/FCF of -3.30 falls within the Historic Trend Line -Fairly Valued range.
AVITA Medical Inc (RCEL) has a current Price-to-Book (P/B) ratio of -16.24. Compared to its 3-year average P/B ratio of 5.54 , the current P/B ratio is approximately -393.10% higher. Relative to its 5-year average P/B ratio of 4.73, the current P/B ratio is about -443.17% higher. AVITA Medical Inc (RCEL) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -17.38%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -13.80% , the current FCF yield is about -100.00% lower.
-16.24
P/B
Median3y
5.54
Median5y
4.73
-34.69
FCF Yield
Median3y
-17.38
Median5y
-13.80
Competitors Valuation Multiple
The average P/S ratio for RCEL's competitors is , providing a benchmark for relative valuation. AVITA Medical Inc Corp (RCEL) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -12.71%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RCEL decreased by 72.27% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from -82.91 to -77.29.
The secondary factor is the Revenue Growth, contributed -12.71%to the performance.
Overall, the performance of RCEL in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is AVITA Medical Inc (RCEL) currently overvalued or undervalued?
What is AVITA Medical Inc (RCEL) fair value?
How does RCEL's valuation metrics compare to the industry average?
What is the current P/B ratio for AVITA Medical Inc (RCEL) as of Dec 05 2025?
What is the current FCF Yield for AVITA Medical Inc (RCEL) as of Dec 05 2025?
What is the current Forward P/E ratio for AVITA Medical Inc (RCEL) as of Dec 05 2025?